Moreover, PRI-724 treatment efficiently downregulated p21 in a concentration-dependent manner in drug-naïve and trametinib- and vemurafenib-resistant melanoma cells (Figure 7A,B). The gene discussed is CDKN1A; the disease is melanoma.